U.S. Stock Market Midday Update: Aditxt's stock price soared 12.16%, trading volume surged, and market volatility has drawn attention

U.S. Stock Market Midday Update Aditxt, up 12.16%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry AbbVie down 1.67%. Based on recent key news: On November 25, AbbVie launched the AbbVie Biotechnology Innovation Award in collaboration with adMare BioInnovations, aimed at promoting innovation and growth in Quebec's life sciences sector. This initiative may enhance the company's influence in the biotechnology field and attract investor attention. On November 26, Berenberg Bank analyst Luisa Hector maintained a buy rating on AbbVie with a target price of $270. The analyst's positive rating may provide support for the stock price. On November 24, AbbVie will participate in the Piper Sandler Annual Healthcare Conference, where the company's management will discuss. This may provide the company an opportunity to showcase its strategies and future plans, impacting investor sentiment. The healthcare industry has shown stability recently, with attention on policy changes. Precision Science up 0.41%. Based on recent news: On November 24, Jefferies downgraded Precision Science's rating from "Buy" to "Hold," but raised the target price from $90 to $105. Jefferies believes that due to Abbott Laboratories' $23 billion acquisition of Precision Science, the stock price will approach the transaction price, limiting the upside potential. On November 24, FactSet's latest survey showed that 16 analysts raised the median target price for Precision Science from $97.5 to $105, an increase of 7.69%. Among them, 8 analysts gave optimistic ratings, while 16 remained neutral. On November 24, Craig-Hallum's William Bonello downgraded Precision Science's rating to "Hold," with a target price of $105. Nevertheless, Citi upgraded Precision Science's rating to "Buy" on November 21. The overall market has performed well recently, with major indices rising. Amgen up 0.98%. Based on recent news: On November 27, Bernstein analyst Courtney Breen maintained a buy rating on Amgen with a target price of $335. This move has boosted market confidence in the stock, driving the price up. On November 26, NVIDIA, AT&T, and Amgen outperformed their peers due to AI growth, 5G expansion, and strong pharmaceutical sales, boosting investor optimism and further driving up the stock price On November 24th, Nancy A. Grygiel, Senior Vice President and Chief Commercial Officer of Amgen, sold 3,139 shares of the company's stock. Nevertheless, the market remains optimistic about the company's overall prospects, and this did not negatively impact the stock price. AI growth and 5G expansion boosted market sentiment. Stocks ranked among the top in industry market capitalization Gilead Sciences rose 0.66%. Based on recent key news: On November 24th, Gilead Sciences reached an agreement with Sprint Bioscience to acquire its cancer project TREX1. The deal includes a $14 million upfront payment, as well as milestone payments of up to $400 million. This strategic acquisition enhances Gilead's competitiveness in the cancer treatment field, driving the stock price up. On November 25th, analyst Seigerman pointed out that Gilead's market valuation is discounted compared to other large-cap stocks, considering it an attractive investment opportunity and giving it a buy rating. This positive assessment further boosted market confidence, supporting the stock price increase. On November 24th, Truist Financial maintained a buy rating on Gilead with a target price of $140. Analysts' optimistic expectations provided support for the stock price. The pharmaceutical industry is driven by innovation, with significant capital inflows